Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage immuno-oncology company focused on developing new therapeutics to meaningfully fight cancer, improve treatment outcomes and transform the lives of cancer patients.

Aptevo molecules are designed for clinical impact, safety and combinability with existing standards of care and emerging therapies.

Aptevo Pipeline Carousel — Slide Transition

For Investors

Aptevo-NASDAQ
View the Corporate Presentation
aptevo-news
Latest News & Accomplishments
The Company has demonstrated clinical proof-of-concept in AML and developed a robust pipeline of drug candidates. Together, these programs are designed to position the Company to build shareholder value by advancing differentiated oncology assets across multiple high-growth markets.